Stem Cells and Gene Therapy

Stem Cells and Gene Therapy Researchers take a second look at using stem cells to treat HIV By Bob Grant Related Articles 5 HIV Treatment Strategies A piggyback attack: Using the common cold to deliver an HIV vaccine The best offense? CCR5 inhibitors, with one now on the market, suggest it may be a good defense Solving the viral spike: Can structural biology find a chink in HIV's armor? Reconstructing early HIV: The search for immunogens d

Written byBob Grant
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

By Bob Grant

5 HIV Treatment Strategies

A piggyback attack: Using the common cold to deliver an HIV vaccine

The best offense? CCR5 inhibitors, with one now on the market, suggest it may be a good defense

Solving the viral spike: Can structural biology find a chink in HIV's armor?

Reconstructing early HIV: The search for immunogens delves into the virus' past

Profile: A Receptive Leader: Panacos' Graham Allaway

PODCAST: Andrea Gawrylewski interviews NIAID director Anthony Fauci, who gives his take on HIV research priorities.

Stem cells enjoyed a short run as potential gene therapy vehicles in the 1990s. Most approaches suffered, however, from low expression levels and low transduction efficiencies in target cells. Though researchers had developed a rich array of anti-HIV genes, including antisense and virion fusion inhibitors, RNA decoys, and short hairpin RNAs, their in vitro effectiveness did not translate into significant therapeutic effects in patients.

Today, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies